bioAffinity Technologies, Inc. (NASDAQ:BIAF)
| Market Cap | $10.94M-91.6% |
| Revenue (ttm) | $5.53M-18.5% |
| Net Income | -$15.41M-4.6% |
| EPS | -$2.45+82.2% |
| Shares Out | 6.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,871.887 |
| Open | $1.80 |
| Previous Close | $1.85 |
| Day's Range | $1.69 - $1.84 |
| 52-Week Range | $1.69 - $80.70 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Apr 5, 2027 |
About BIAF
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Apr 5, 2027Earnings report
$BIAF stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BIAF holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BIAF's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BIAF Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BIAF patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BIAF from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BIAF
| VXFVanguard Extended Market ETF | $10.77K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BIAF’s recent data — informational, not investment advice
What’s Behind the Score
News check: Record test volume and commercialization momentum offset by Q3 earnings miss and declining sales, creating mixed near-term signals.
